AroCell Q2 2022: Good cost control, somewhat lower sales

Research Update

2022-08-18

08:00

Redeye returns with a more detailed take on the Q2 report and notes lower costs than expected and anticipate a continuous upswing of TUBEX sales while lowering FY 2022E sales somewhat. We reiterate our fair value range.

OB

Oscar Bergman

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.